Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Completed · Phase 1

Conditions studied: Lymphoma

In brief

RATIONALE: Interleukin-12 may stimulate a person's white blood cells to kill lymphoma cells. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 plus rituximab in treating patients who have non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00004260

Run by

Mayo Clinic

Starts

1999-10-01

Expected to finish

2003-06-01

Last updated by the study team

2011-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.